Cytotoxic T Lymphocytes
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (31 May 2016) | Viewed by 226
Special Issue Editors
Interests: cytotoxic T cells; cytoskeleton; cancer; immunology; cell migration
Special Issue Information
Dear Colleagues,
As central effectors of adaptive immunity, cytotoxic T lymphocytes are essential for efficient immunosurveillance and clearance of pathogens and transformed cells. Aberrant cytotoxic T cell activity, both insufficient and excessive, underlies a number of prevalent immunodeficiencies and autoimmune diseases.
Novel immunotherapeutic strategies that aim at the activation of targeted cytotoxicity are currently at the forefront in the treatment of infectious diseases and cancer. In fact, recent developments in adoptive T cell therapies and antibody-based immune checkpoint inhibitors have seen some of the greatest breakthroughs in the treatment of refractory metastatic malignancies.
Understanding the processes driving cytotoxic T cell activity in both health and disease is therefore key for advancing therapies that either curb or potentiate T cell functions in a wide variety of pathologies.
This Special Issue of Antibodies focuses on the fundamental mechanisms that underpin cytotoxic T cell responses, as well the development of new therapeutic agents that modulate cytotoxic T cell function.
Dr. Maté Biro
Dr. Marcia Munoz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cytotoxic T cells
- immunotherapy
- cancer
- adoptive T cell therapy
- immune checkpoint inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
